Antigen-specific active immunotherapy for ovarian cancer

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 9, 2014, Pages

  Leffers, Ninke ^a   Daemen, Toos ^a   Helfrich, Wijnand ^a   Boezen, H Marike ^a   Cohlen, Ben J ^b   Melief, Cornelis J M ^c   Nijman, Hans W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; MONOCLONAL ANTIBODY;

ACTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; EVIDENCE BASED MEDICINE; FEASIBILITY STUDY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ACTIVE IMMUNIZATION; ADVERSE EFFECTS; FEMALE; IMMUNOLOGY; META ANALYSIS; MOLECULARLY TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROCEDURES;

ANTIBODIES, MONOCLONAL; CA-125 ANTIGEN; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; MOLECULAR TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84942752264     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007287.pub3     Document Type: Review

References (157)

1. Baumann K, Pfisterer J, Wimberger P, Burchardi P, Kurzeder C, du Bois A, et al. Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO study group. Gynecologic Oncology 2011;123:27-32.
2. Berek JS, Ehlen TG, Gordon A, Nicodemus CF, Schultes B, Whiteside TL, et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001.
3. Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J, et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology 2004;22(17):3507-16.
4. Berek JS, Taylor PT, Nicodemus CF. CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy 2008;31(2):207-14.
5. Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology 2009;27:418-25.
6. Berek J, Taylor PT, McGuire WP, Smith LM, Schultes B, Nicodemus CF. Evaluation of maintenance mono-immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). 2008 ASCO Annual Meeting Proceedings. 2008.
7. Berinstein NL, Karkada M, Morse MM, Nemunaitis JJ, Chatta G, Kaufman H, et al. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer. Journal of Translational Medicine 2012;10:156.
8. Berinstein NL, Oza AM, Odunsi K, Karkada M, Villella JA, Nemunaitis JJ, et al. Effect of oral cyclophosphamide on the immunogenicity of DPX-Survivac in ovarian cancer patients: results of a phase I study. American Society of Clinical Oncology Annual Meeting. 2013.
9. Braly P, Chu C, Collins Y, Edwards R, Gordon A, McGuire W, et al. Prospective evaluation of front-line chemo-immunotherapy (C-IT) with oregovomab (2 alternative dosing schedules) carboplatin-paclitaxel (C-P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007.
10. Braly P, Nicodemus CF, Chu C, Collins Y, Edwards R, Gordon A, et al. The immune adjuvant properties of front-line carboplatin-paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo-immunotherapy in advanced ovarian cancer. Journal of Immunotherapy 2009;32:54-65.
11. Method M, Gordon A, Smith LM, Nicodemus CF. Oregovomab immune-modulating antibody therapy concurrent tot standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006.
12. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96(9):3102-8.
13. Chianese-Bullock KA, Irvin WP, Jr, Petroni GR, Murphy C, Smolkin M, Olson WC, et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. Journal of Immunotherapy 2008;31(4):420-30.
14. Chu CS, Boyer J, Coukos G, Rubin SC, Morgan MA, Bendig DL, et al. Autologous dendritic cell (IDD-6) vaccination as consolidation for advanced ovarian cancer. Society of Gynecologic Oncologists: Annual Meeting on Women's Cancer. 2008.
15. Chu CS, Boyer J, Schullery DS, Gimotty PH, Gamerman V, Bender J, et al. Phase I/II. randomized tiral of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy 2012;61:629-41.
16. Dhodapkar M, Zhao B, Wang D, Lutzky RD, Carvajal RD, Keohan M, et al. A phase I trial of a novel vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205 in combination with toll-like receptor agonists. Society for Immunotherapy of Cancer Annual Meeting. 2012.
17. Diefenbach CSM, Gnjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clinical Cancer Research 2008;14(9):2740-8.
18. Ehlen TG, Hoskins PJ, Miller D, Whiteside TL, Nicodemus CF, Schultes BC, et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer 2005;15(6):1023-34.
19. Freedman RS, Kudelka AP, Verschraegen CF, Edwards CL, Tomasovic B, Kaplan A, et al. Therapeutic anti-cancer vaccine: a randomized double blind dose comparison study of sialyl Tn-KLH with Detox-B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1998.
20. Termrungruanglert W, Kudelka AP, Verschraegen CF, Freedman RS, Edwards CL, Tomasovic B, et al. Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN-K with detox-B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1996.
21. Galanis E, Hartmann L, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research 2010;70(3):875-82.
22. Goh J, CAN-003 Study Team, Gargosky SE, Gray H. Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission. European Cancer Congress. 2013.
23. Gordon AN, Schultes BC, Gallion H, Edwards R, Whiteside TL, Cermak JM, et al. CA125-and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecologic Oncology 2004;94(2):340-51.
24. Gribben JG, Ryan DP, Urban RG, Hedley ML, Beach K, Nealon P, et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research 2005;11(12):4430-6.
25. Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clinical Cancer Research 2008;14:3060-9.
26. Heiss MM, Maruwa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III. trial. International Journal of Cancer 2010;127:2209-21.
27. ImhoffM, Lipovac M, Angleitner-Boubenizek L, Barta J, Gomez I, Hrdina A, et al. Double-loaded mature dendritic cell (DC) therapy for non-HLA-restricted patients with advanced ovarian cancer: final results of a clincal phase I study. American Society of Clinical Oncolocy Annual Meeting. 2013.
28. Kaumaya PTP, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology 2009;27(31):5270-7.
29. Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, et al. A live-attenuated listeria vaccine (ANZ-100) and a live-attenuated listeria vaccine expressin mesothelin (CRS-207) for advanced cancers: pahse I studies of safety and immune induction. Clinical Cancer Research 2012;18(3):858-68.
30. Leffers N, Lambeck AJ, Gooden MJ, Hoogeboom BN, Wolf R, Hamming IE, et al. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II. trial. International Journal of Cancer 2009;May 28:[Epub ahead of print].
31. Leffers N, Vermeij R, Hoogeboom BN, Schultze UR, Wolf R, Hamming IE, et al. Long-term clinical and immunological effects of p53-SLP vaccine in patients with ovarian cancer. International Journal of Cancer 2012;130:105-12.
32. Letsch A, Scheibenbogen C, Asemissen AM, Zimmermann K, Knodler M, Völker-Call M, et al. Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1 expressing solid tumors demonstrates clinical and immunological efficacy. Onkologie 2011;34(suppl 6):194.
33. Ma J, Zhou L, Wang D. Functional mimicry of an anti-idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research 2002;93(1):78-84.
34. MacLean GD, Bowen-Yacyshyn MB, Samuel J, Meikle A, Stuart G, Nation J, et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. Journal of Immunotherapy 1992;11(4):292-305.
35. MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. Journal of Immunotherapy With Emphasis on Tumor Immunology 1996;19(1):59-68.
36. Method M, Gordon A, Finkler N, Fingert H, Nicodemus CF, Whiteside TL, et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002.
37. Mobus VJ, Baum RP, Bolle M, Kreienberg R, Noujaim AA, Schultes BC, et al. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology 2003;189(1):28-36.
38. Mohebtash M, Madan R, Tsang K, Arlen Ph, Pazdur M, Jones J, et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. American Association of Cancer Research Annual Meeting. 2009.
39. Mohebtash M, Tsang KY, Huen NY, Poole DJ, Jochems C, Jones J, et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research 2011;17(22):7164-73.
40. Morse MA, Secord AA, Blackwell K, Hobeika AM, Sinnathamby G, Osada T, et al. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell repsonses against breast and ovarian cancer. Clinical Cancer Research 2011;17(10):3408-19.
41. Nicholson S, Bomphray CC, Thomas H, McIndoe A, Barton D, Gore M, et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy 2004;53(9):809-16.
42. Nishikawa H, Qian F, Tsuji T, Ritter G, Old LJ, Gnjatic S, et al. Influence of CD4(+)CD25(+) regulatory T cells on low/high-avidity CD4(+) T cells following peptide vaccination. Journal of Immunology 2006;176(10):6340-6.
43. Noujaim AA, Schultes BC, Baum RP, Madiyalakan R. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biotherapy & Radiopharmaceuticals 2001;16(3):187-203.
44. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II. specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 2007;104(31):12837-42.
45. Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller M, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. PNAS 2012;109(15):5797-802.
46. Odunsi K, Rodabaugh K, Lele S, Old LJ, Matsuzaki J, Qian F, et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY-ESO-1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2007.
47. Dohi S, Ohno S, Ohno Y, Takakura M, Kyo S, Soma GI, et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Research 2001;31:2441-6.
48. Ohno S, Kyo S, Myojo S, Dohi S, Ishizaki J, Miyamoto KI, et al. Wilms'tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Research 2009;29:4779-84.
49. Peethambaram PP, Melisko ME, Rinn KJ, Alberts SR, Provost NM, Jones LA, et al. A phase I trial of immunotherapy with Lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express Her-2/neu. Clinical Cancer Research 2009;15(18):5937-44.
50. Pfisterer J, du BA, Sehouli J, Loibl S, Reinartz S, Reuss A, et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Annals of Oncology 2006;17(10):1568-77.
51. Herrin V, Achtar M, Steinberg S, Whiteside TL, Wieckowsk E, Czystowska M, et al. A randomized phase II. p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide-pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology Annual Meeting. 2007.
52. Herrin V, Behrens RJ, Achtar M, Monahan B, Bernstein S, Brent-Steele T, et al. Wild-type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom. American Society of Clinical Oncology Annual Meeting. 2003.
53. Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, et al. A gynecologic oncology group phase II. trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology Immunotherapy 2012;61:374-84.
54. Reinartz S, Kohler S, Schlebusch H, Krista K, Giffels P, Renke K, et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research 2004;10(5):1580-7.
55. Wagner U, Kohler S, Reinartz S, Giffels P, Huober J, Renke K, et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research 2001;7(5):1154-62.
56. Sabbatini PJ, Kudryashov V, Ragupathi G, Danishefsky SJ, Livingston PO, Bornmann W, et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Clinical Cancer Research 2000;87(1):79-85.
57. Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research 2006;12(18):5503-10.
58. Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research 2007;13:4170-7.
59. Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research 2012;18(23):6497-508.
60. Sabbatini P, Harther P, Scambia G, Sehouli J, Meier W, Wimberger P, et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III. trial of the AGO OVAR, COGI, GINECO and GEICO - the MIMOSA study. Journal of Clinical Oncology 2013;31(12):1554-61.
61. Sandmaier BM, Oparin DV, Holmberg LA, Reddish MA, MacLean GD, Longenecker BM. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. Journal of Immunotherapy 1999;22(1):54-66.
62. Schultes B, Yang R, Agopsowicz K, Kuzma M, Dharampaul S, Baum R, et al. Anti-idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex-Mab-B43.13. American Society of Clinical Oncology Annual Meeting. 1999.
63. Schultes BC, Baum RP, Niesen A, Noujaim AA, Madiyalakan R. Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy 1998;46(4):201-12.
64. Ströhlein MA, Siegel R, Jäger M, Lindhofer H, Jauch KW, Heiss MM. Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental & Clinical Cancer Research 2009;28:18.
65. Takeuchi S, Shoji T, Kagabu M, Honda T, Miura F, Omi H, et al. A phase I/II. study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2013.
66. Tsuda N, Mochizuki K, Harada M, Sukehiro A, Kawano K, Yamada A, et al. Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy 2004;27(1):60-72.
67. van Zanten-Przybysz I, MolthoffC, Gebbinck JK, von Mensdorff-Pouilly S, Verstraeten R, Kenemans P, et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology 2002;128(9):484-92.
68. Vermeij R, Leffers N, Hoogeboom BN, Hamming LE, Wolf R, Reyners AKL, et al. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II. study. International Journal of Cancer 2012;131:E670-80.
69. Wagner U. Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma 1993;12(5):521-8.
70. Wagner U, Reinsberg J, Schmidt S, Mallmann P, Schmolling J, Schultes B, et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics 1994;24-25:237-42.
71. Anderson BW, Kudelka AP, Honda T, Pollack MS, Gershenson DM, Gillogly MA, et al. Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides. Cancer Immunology, Immunotherapy 2000;49(9):459-68.
72. Bender A, Karbach J, Neumann A, Jager D, Al-Batran SE, Atmaca A, et al. LUD 00-009: Phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immunology, Immunotherapy 2007;7:16.
73. Bernal SD, Ona ET, Riego-Javier E, de Villa R, Cristal-Luna GR, Laguatan JB, et al. Anticancer immune reactivity and long-term survival after treatment of metastatic ovarian cancer with dendritic cells. Oncology Letters 2012;3:66-74.
74. Carbone DP, Ciernik IF, Kelley MJ, Smith MC, Nadaf S, Kavanaugh D, et al. Immunization with mutant p53-and K-ras-derived peptides in cancer patients: immune response and clinical outcome. Journal of Clinical Oncology 2005;23(22):5099-107.
75. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clinical Cancer Research 1999;5(6):1289-97.
76. Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clinical Cancer Research 2000;6(4):1347-50.
77. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. Journal of Clinical Oncology 2002;20(11):2624-32.
78. Disis ML, Rinn K, Knutson KL, Davis D, Caron D, dela Rosa C, et al. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 2002;99(8):2845-50.
79. Disis ML, Goodell V, Schiffman K, Knutson KL. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. Journal of Clinical Immunology 2004;24(5):571-8.
80. Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, et al. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine. Journal of Clinical Oncology 2004;22(10):1916-25.
81. Galanis E, Atherton P, Dowdy S, Cliby W, Haluska P, Long H, et al. Intraperitoneal (IP) administration of an oncolytic measles virus (MV) strain expressing the sodium iodine symporter gene in patients (pts) with advanced ovarian cancer (ovca). American Society of Gene& Cell Therapy (ASGCT) Annual Meeting. 2013.
82. Haakenstad H, Suso EMI, Rasmussen AM, Larsen SS, Dueland S, Lilleby W, et al. Clinical use of fast DCs transfected with hTERT and Survivin mRNA - an effective and simplified cancer vaccine approach. European Group for Blood and Marrow Transplantation Annual Meeting. 2012.
83. Kvalheim G, Suso E, Rasmussen A, Honnashagen T, Dueland S, Gaudernack G. Fast DCs transfected with hTERT and Survivin mRNA - a novel, effective and simplified cancer vaccine approach. In European Group for Blood and Marrow Transplantation Annual Meeting. 2011.
84. Hasumi K, Aoki Y, watanabe R, Hankey KG, Mann DL. Therapeutic response in patients with advanced malignancies treated with combined dendritic cell-activated T cell based immunotherapy and intensity-modulated radiotherapy. Cancers 2011;3:2223-42.
85. Hernando JJ, Park TW, Kubler K, Offergeld R, Schlebusch H, Bauknecht T. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunology, Immunotherapy 2002;51(1):45-52.
86. Hernando JJ, Park T-W, Fischer H-P, Zivanovic O, Braun M, Polcher M, et al. Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-(alpha) for relapsed metastatic ovarian cancer. Lancet Oncology 2007;8(5):451-4.
87. Holmberg LA, Oparin DV, Gooley T, Lilleby K, Bensinger W, Reddish MA, et al. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant 2000;25(12):1233-41.
88. Hui KM, Ang PT, Huang L, Tay SK. Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes. Gene Therapy 1997;4(8):783-90.
89. Jager E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proceedings of the National Academy of Sciences of the United States of America 2006;103(39):14453-8.
90. Coukos G, Powell D, Kandalaft L, Smith L, Chu C, Rubin S, et al. Autologous whole-tumor antigen combinatorial immunotherapy for recurrent ovarian cancer. Gynecologic Oncology 2010;116:s130.
91. Kandalaft LE, Powell DJ, Smith L, Adams S, Liao J, Hageman A, et al. Autologous whole-tumor anitgen combinatorial immunotherapy for recurrent ovarian cancer. Journal of Immunotherapy 2010;33(8):878.
92. Karbach J, Gnjatic S, Bender A, Neumann A, Weidmann E, Yuan J, et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. International Journal of Cancer 2010;126:909-18.
93. Kato Y. WT1 peptide pulsed dendritic cell therapy with activated T lymphocytes therapy for advanced cancers. Gan To Kagaku Ryoho 2010;37(12):2240-2.
94. Khranovska NM, Svyntsytsky VS, Potebnya GP, Vorobyova LI, Skachkova, Tsyp NP, et al. New dendritic cell vaccine therapy approach - randomized phase I/II. study in III.-IV stage ovarian cancer patients. In: European Multidisciplinary Cancer Conference (ECCO ESMO ESTRO). 2011.
95. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. Journal of Clinical Investigation 2001;107(4):477-84.
96. Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clinical Cancer Research 2002;8(5):1014-8.
97. Letsch A, Asemissen AM, Zimmermann K, Bauer S, Stather D, Völker-Call M, et al. Different quality of T cell repsonses to WT1 peptide vaccination in patients with AML/MDS and patients with solid tumors. Journal of Immunotherapy. 2008; Vol. 31:943-4.
98. Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clinical Cancer Research 2006;12(3 Pt 1):869-77.
99. Manjunath SR, Ramanan G, Dedeepiya VD, Terunuma H, Deng X, Baskar S, et al. Autologous immune enhancement therapy in recurrent ovarian cancer with metastases: a case report. Case Reports in Oncology 2012;5:114-8.
100. Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. Journal of Clinical Oncology 2005;23:720-31.
101. Miotti S, Negri DR, Valota O, Calabrese M, Bolhuis RL, Gratama JW, et al. Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival. International Journal of Cancer 1999;84(1):62-8.
102. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clinical Cancer Research 1999;5(6):1331-8.
103. Morse MA, Clay TM, Colling K, Hobeika A, Grabstein K, Cheever MA, et al. Her2 dendritic cell vaccines. Clinical Breast Cancer 2003;3 suppl. 4:S164-72.
104. Morse MA, Chapman R, Powerdly J, Blackwell K, Keler T, Green J, et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clinical Cancer Research 2011;17(14):4844-53.
105. Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clinical Cancer Research 2002;8(11):3407-18.
106. Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clinical Cancer Research 2004;10(14):4688-98.
107. Reddish MA, MacLean GD, Poppema S, Berg A, Longenecker BM. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunology, Immunotherapy 1996;42(5):303-9.
108. Salazar LG, Murray JL, Disis ML, Cheever M. A phase I vaccine trial of a HER-2/neu peptide incorporated into PLG microspheres in patients with advanced stage HER2-expressing cancers. ASCO Annual Meeting. 2006.
109. Schiffman K, Rinn K, Disis ML. Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients. Breast Cancer Research and Treatment 2002;74(1):17-23.
110. Yacyshyn MB, Poppema S, Berg A, MacLean GD, Reddish MA, Meikle A, et al. CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy. International Journal of Cancer 1995;61(4):470-4.
111. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Research 1998;58(21):4902-8.
112. University of Washington. Her-2/Neu vaccine plus GM-CSF in treating patients with stage III. or stage IV breast, ovarian, or non-small cell lung cancer. clinicaltrials.gov.
113. Duke University. Biological therapy in treating patients with metastatic cancer. clinicaltrials.gov.
114. Memorial Sloan - Kettering Cancer Center. Vaccine therapy in treating patients with ovarian, fallopian tube, or peritoneal cancer. clinicaltrials.gov.
115. National Cancer Institute (NCI). An open label pilot study to evaluate the safety and tolerability of PANVAC-V (Vaccinia) and PANVAC-F (Fowlpox) in combination with sargramostim in adults with metastatic carcinoma. clinicaltrials.gov.
116. University of Virginia Cancer Center and National Cancer Institute (NCI). Evaluation of the immunogenicity of vaccination with synthetic peptides in adjuvant in patients with advanced ovarian, primary peritoneal, or fallopian tube cancer. clinicaltrials.gov.
117. Eisai Medical Research Inc. A phase 1 open-label study of the safety and feasibility of ZYC300 administration with cyclophosphamide pre-dosing. clinicaltrials.gov.
118. Roswell Park Cancer Institute and National Cancer Institute (NCI). Phase I study of ALVAC(2)-NY-ESO-1(M)/TRICOM in patients with epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumors express NY-ESO-1 or LAGE-1 antigen. clinicaltrilas.gov.
119. Gynecologic Oncology Group and National Cancer Institute (NCI). A phase III. randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933) + OPT-821 Versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission. clinicaltrials.gov.
120. National Cancer Institute (NCI). Open label phase I study to evaluate the safety and tolerability of vaccine (GI-6207) consisting of whole, heat-killed recombinant saccharomyces cerevisiae genetically modified to express CEA protein in adults with metastatic CEA-expressing carcinoma. clinicaltrials.gov.
121. Roswell Park Cancer Institute and National Cancer Institute (NCI). A phase I clinical trial of NY-ESO-1 protein immunization in combination with 5-AZA-2'-deoxycytidine (decitabine) in patients receiving liposomal doxorubicin for recurrent epithelial ovarian or primary peritoneal carcinoma. clinicaltrials.gov.
122. Celidex Therapeutics. A study of CDx-1401 in patients with malignancies known to express NY-ESO-1. clinicaltrials.gov.
123. Memorial Sloan - Kettering Cancer Center. Polyvalent vaccine-KLH conjugate + Opt-821 given in combination with bevacuzimab. clinicaltrials.gov.
124. Memorial Sloan - Kettering Cancer Center. Unimolecular pentavalent (Globo-H-GM2-sTN-TF-Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. clinicaltrials.gov.
125. University of Washington. Vaccine therapy in treating patients with stage III.-IV or recurrent ovarian cancer. clinicaltrials.gov.
126. Oslo University Hospital. Trial of vaccine therapy in recurrent platinum sensitive ovarian cancer patients. clinicaltrials.gov.
127. Pravin Kaumaya. Vaccine therapy in treating patients with metastatic solid tumors. clinicaltrials.gov.
128. Roswell Park Cancer Institute. Vaccine therapy with or without sirolimus in treating patients with NY-ESO-1 expressing solid tumors. clinicaltrials.gov.
129. Roswell Park Cancer Institute. Sirolimus and vaccine therapy in treating patients with stage II-IV ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer. clinicaltrials.gov.
130. COL George Peoples. Phase Ib trial of folate binding protein vaccine in ovarian cancer. clinicaltrials.gov.
131. Instituto de Investigacao em Imunologia. Clinical trial of a therapeutic vaccine with NY-ESO-1 in combination with the adjuvant monophosphoryl lipid A (MPLA). clinicaltrials.gov.
132. Mayo Clinic. Cyclophosphamide and vaccine therapy in treating patients with stage II-III. breast, ovarian, primary peritoneal, or fallopian tube cancer. clinicaltrials.gov.
133. Quest PharmaTech Inc. A controlled study of the effectiveness of oregovomab (antibody) plus chemotherapy in advanced ovarian cancer. clinicaltrials.gov.
134. Sunovion. Clinical study of WT2725 in patients with advanced solid malignancies. clinicaltrials.gov.
135. Leiden University Medical Center. Chemo-immunotherapy (gemcitabine, interferon-alpha 2b and p53 SLP) in patients with platinum-resistant ovarian cancer (CHIP). clinicaltrials.gov.
136. Roswell Park Cancer Institute. Decitabine, vaccine therapy, and pegylated liposomal doxorubicin hydrochloride in treating patients with recurrent ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer. clinicaltrials.gov.
137. Agarwal R, Linch M, Kaye SB. Novel therapeutic agents in ovarian cancer. European Journal of Surgical Oncology 2006;32(8):875-86.
138. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clinical Cancer Research 2006;12(3):878-87.
139. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. International Journal of Gynaecology and Obstetrics 2000;70(2):209-62.
140. Brighton Collaboration. www.brightoncollaboration.org.
141. Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C, et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunology, Immunotherapy 2008;57(3):289-302.
142. Common Terminology Criteria for Adverse Events v4.03. National Institutes of Health, US Department of Health and Human Services2009publication # 09-7473.
143. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F et al. International Stroke Trial Collaborative Group, European Carotid Surgery Trial Collaborative Group. Evaluating non-randomised intervention studies. Health Technology Assessment 2003;7(27):1-173.
144. Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, et al. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. American Journal of Clinical Pathology 2006;125(3):451-8.
145. Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clinical Cancer Research 2008;14(11):3536-44.
146. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clinical Cancer Research 2008;14(5):1455-63.
147. Leffers N, Daemen CAHH, van der Zee AGJ, Nijman HW. Multimodality treatment warranted for ovarian cancer: immunotherapy, a prerequisite to improve prognosis for this vicious disease. Immunotherapy 2009;1(2):163-5.
148. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a Cancer Journal for Clinicians 2005;55(2):74-108.
149. Raspollini MR, Castiglione F, Rossi Degl'innocenti D, Amunni G, Villanucci A, Garbini F, et al. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Annals of Oncology 2005;16(4):590-6.
150. Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). Journal of the National Cancer Institute 2004;96(6):487-8.
151. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favourable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 2005;102(51):18538-43.
152. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000;92(3):205-16.
153. Thigpen JT. Chemotherapy for advanced ovarian cancer: overview of randomized trials. Seminars in Oncology 2000;27(3 Suppl 7):11-6.
154. Trotti A, Colevas A, Setser V, Rusch D, Jaques V, Budach C, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology 2003;13(3):176-81A.
155. World Health Organization. Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization, 1979.
156. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New England Journal of Medicine 2003;348(3):203-13.
157. Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief K etal. Antigen-specific active immunotherapy for ovarian cancer. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD007287.pub2]